Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1217326.RADG7PviTvwt-ECkAo4oJJEw_ri_NDqh83_Yk2GxJERBg130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1217326.RADG7PviTvwt-ECkAo4oJJEw_ri_NDqh83_Yk2GxJERBg130_assertion type Assertion NP1217326.RADG7PviTvwt-ECkAo4oJJEw_ri_NDqh83_Yk2GxJERBg130_head.
- NP1217326.RADG7PviTvwt-ECkAo4oJJEw_ri_NDqh83_Yk2GxJERBg130_assertion description "[Therefore, interrupting the RAS-MAPK pathway by an ERK1/2 inhibitor (apigenin) or an AURKB inhibitor (barasertib) might be a new strategy for overcoming cetuximab resistance in HNSCC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1217326.RADG7PviTvwt-ECkAo4oJJEw_ri_NDqh83_Yk2GxJERBg130_provenance.
- NP1217326.RADG7PviTvwt-ECkAo4oJJEw_ri_NDqh83_Yk2GxJERBg130_assertion evidence source_evidence_literature NP1217326.RADG7PviTvwt-ECkAo4oJJEw_ri_NDqh83_Yk2GxJERBg130_provenance.
- NP1217326.RADG7PviTvwt-ECkAo4oJJEw_ri_NDqh83_Yk2GxJERBg130_assertion SIO_000772 25192874 NP1217326.RADG7PviTvwt-ECkAo4oJJEw_ri_NDqh83_Yk2GxJERBg130_provenance.
- NP1217326.RADG7PviTvwt-ECkAo4oJJEw_ri_NDqh83_Yk2GxJERBg130_assertion wasDerivedFrom befree-2016 NP1217326.RADG7PviTvwt-ECkAo4oJJEw_ri_NDqh83_Yk2GxJERBg130_provenance.
- NP1217326.RADG7PviTvwt-ECkAo4oJJEw_ri_NDqh83_Yk2GxJERBg130_assertion wasGeneratedBy ECO_0000203 NP1217326.RADG7PviTvwt-ECkAo4oJJEw_ri_NDqh83_Yk2GxJERBg130_provenance.